Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

NCT ID: NCT03117036

Last Updated: 2025-05-21

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 600 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-03-01
• Study Completion Date: 2026-12-28

Brief Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Detailed Description

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.

1. Registration after informed consent.

2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood

3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood

4. Regular monitoring disease status and update of survival status

5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Conditions

Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Lymphoma

Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.

Chemotherapy

Intervention Type: DRUG

Systemic chemotherapy with curative intent

Interventions

Chemotherapy

Systemic chemotherapy with curative intent

Intervention Type: DRUG

Other Intervention Names

Treatment

Eligibility Criteria

Inclusion Criteria

1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas

2. 20 years

3. Patients requiring systemic chemotherapy with curative intent

4. Written informed consent

Exclusion Criteria

1. Myeloid malignancy

2. Multiple myeloma

3. Patients do not require systemic chemotherapy with curative intent

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samsung Genomic Institute

UNKNOWN

Sponsor Role: collaborator

Samsung Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Seok Jin Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center

Locations

Samsung Medical Center

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Seok Jin Kim, MD, PhD

Role: CONTACT

kstwoh@skku.edu

+82234101766

Facility Contacts

Seok Jin Kim, MD, PhD

Role: primary

kstwoh@skku.edu

82-2-3410-1766

Other Identifiers

2016-11-040

Identifier Type: -

Identifier Source: org_study_id